この記事の翻訳を準備しています。それまでの間、英語の原文を表示します。
ビジネス · 2023/5/21 分で読めます
A Risk-Based Approach to Monitoring of Clinical Investigations-Questions and Answers; Guidance for Industry; Correction
ローカル自動翻訳 · 情報源の原言語
概要
The Food and Drug Administration (FDA) is correcting a notice that appeared in the Federal Register of April 12, 2023. The document announced the availability of a final guidance entitled "A Risk-Based Approach to Monitoring of Clinical Investigations--Questions and Answers; Guidance for Industry." The notice of availability for this final guidance was published with an incorrect OMB control number. This document corrects that error.
情報源の原言語: Federal Register — Food and Drug Administration原文の発表を開く →